Skip to content

Ayurvedic Management Of Hepatitis B

CLINICAL EVALUATION OF THE THERAPEUTIC EFFICACY OF SARVAKALPAGHANA VATI AND TOTALA HIMA IN CHRONIC HEPATITIS B

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/014023
Enrollment
50
Registered
2018-05-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K739- Chronic hepatitis, unspecified

Interventions

Intervention1: Sarvakalpaghana vati and totala hima: Sarvakalpaghana vati is prepared from the ghansatva of the Sarvakalpa kwath. whereas totala hima will be prepared as per classical method of hima p

Sponsors

Patanjali Ayurveda College
Lead Sponsor
Dr Prince
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients irrespective of sex, religion, occupation and chronicity will be selected. 2. Patients with two times higher ALT levels than the upper limit of normal value will be selected. 3. Patients with symptoms and signs of hepatitis B, abnormal liver functions and diagnosed cases of Chronic Hepatitis B infection will be registered.

Exclusion criteria

Exclusion criteria: 1. Patients aged >65 years or 2. Pregnant or lactating women will be excluded. 3. Patients who had hepatitis C or other hepatic viral infection, autoimmune hepatitis and drug-induced hepatitis or alcoholic hepatitis will be excluded. 4. Patients with severe complications of the cardiovascular, renal or hematopoietic systems and mental diseases will be excluded. 5. Patients will be excluded having decompensated liver disease. 6. Patients with prolonged or a history of ascites, developed hepato-cellular carcinoma, hepatic encephalopathy, variceal bleeding will be excluded. 7. Patients with a history of using IFN or antiviral agents or corticosteroids or immunosuppressive drugs will also be excluded.

Design outcomes

Primary

MeasureTime frame
All investigations like SGOT, SGPT, HbsAg, Anti-Hbe, PCRTimepoint: before intervention- Each Follow up- After every 2 months

Secondary

MeasureTime frame
All investigations like SGOT, SGPT, HbsAg, Anti-Hbe, PCRTimepoint: After trial of 6 months

Countries

India

Contacts

Public ContactDr Abhishek Bhushan Sharma

Patanjali Bhartiya Ayurvigyan Evam Anusandhan Sansthan, Haridwar

ayu.abhishek@gmail.com9458636020

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026